Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alimera Sciences, Inc. ALIM
$1.61
-$0.04 (-2.42%)
На 18:00, 12 мая 2023
+459.01%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
11563344.00000000
-
week52high
7.92
-
week52low
1.30
-
Revenue
54129000
-
P/E TTM
-1
-
Beta
1.38615900
-
EPS
-2.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 28 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 25 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 15 апр 2021 г. |
| Alliance Global Partners | Neutral | Buy | 21 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SKIBSTED RUSSELL | A | 52500 | 52500 | 09 янв 2023 г. |
| SKIBSTED RUSSELL | A | 17500 | 17500 | 09 янв 2023 г. |
| Parsons Erin | A | 6000 | 6000 | 04 янв 2023 г. |
| Halak Brian K | A | 6000 | 6000 | 04 янв 2023 г. |
| Myers C. Daniel | A | 6000 | 6000 | 04 янв 2023 г. |
| Snisarenko John | A | 6000 | 6000 | 04 янв 2023 г. |
| Largent James R | A | 6000 | 6000 | 04 янв 2023 г. |
| Kong Garheng | A | 6000 | 6000 | 04 янв 2023 г. |
| Pizzo Peter J. III | A | 6000 | 6000 | 04 янв 2023 г. |
| Jones John Philip | A | 32185 | 372 | 31 окт 2022 г. |
Новостная лента
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
GlobeNewsWire
08 мая 2023 г. в 08:00
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 15, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
31 мар 2023 г. в 10:45
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
GlobeNewsWire
24 мар 2023 г. в 16:05
Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time
7 Stocks That Could Implode at Any Moment
InvestorPlace
17 ноя 2022 г. в 15:54
Although it's not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising, investors need to start preparing for the worst.
Alimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 11:46
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Laura Sorel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporate Update Conference Call.